VEGFA and neoplasm: In addition to increases of tumour cell extravasation, discontinuation of anti-VEGF therapy-triggered hepatic microvascular alterations could also potentially promote hepatic cellular carcinoma (HCC) metastasis by a mechanism of facilitating tumour cell intravasation.